Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals Submits Application to FDA Commissioner's National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Down 49.4% in April
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Up 21.7% in March
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Drop in Short Interest
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One
Contrasting Kaleido Biosciences (NASDAQ:KLDO) and Adial Pharmaceuticals (NASDAQ:ADIL)
Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04
Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Decreases By 31.2%
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Drops By 59.6%
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Sees Large Decline in Short Interest
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
All You Need to Know About Adial Pharmaceuticals (ADIL) Rating Upgrade to Buy
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals Completes Successful EOP2 FDA Meeting
Adial Pharmaceuticals Regains Compliance with Nasdaq Stockholders' Equity Listing Requirement
Adial Pharmaceuticals (ADIL) Upgraded to Strong Buy: Here's Why
Adial Pharmaceuticals Files PCT Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to at least 2045
Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals Receives Milestone Payment from Adovate Following Initiation of Phase 1 Study
Adial Pharmaceuticals Announces a Warrant Inducement Transaction for $2.75 Million in Gross Proceeds
Adial Pharmaceuticals Expands Intellectual Property Portfolio with New U.S. Patent Granted for Genetic-Based Treatment of Alcohol and Opioid Use Disorders
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
Why Is Adial Pharmaceuticals (ADIL) Up 61% Today?